SHIONOGI produces vaccine antigens using a unique recombinant protein manufacturing platform developed originally by UMN Pharma. This platform operates on the Baculovirus Expression Vector System (BEVS). In this process, a specialized baculovirus vector delivers genetic information exclusively to insect cells, which then produce large quantities of the target protein. Following this, impurities like insect cells and baculovirus vectors are removed, leaving behind the purified target protein as the active pharmaceutical ingredient.

Feature example

  • Utilizes non-pathogenic elements, avoiding the disease-causing agents themselves.
  • Versatile in developing vaccines against a wide range of pathogens.
  • Suitable for various modes of administration, including injectable, mucosal (e.g., nasal), and transdermal patches.